{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-274291","form_type":"8-K","ticker":"ODTX","cik":"0001882782","company_name":"Odyssey Therapeutics, Inc.","filed_at":"2026-06-17T20:45:18+00:00","discovered_at":"2026-06-17T20:46:00.296399+00:00","generated_at":"2026-06-17T20:46:26.377206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data","bullets":["Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.","Net loss of $38.3M for Q1 2026, comparable to $38.4M in Q1 2025.","R&D expenses $32.3M (down $6.5M YoY); G&A $7.4M (down $0.6M YoY).","Phase 2a proof-of-concept for OD-001: 27% clinical remission, 61% clinical response in UC.","Plan to launch Phase 2b monotherapy and Phase 2a combo trial with vedolizumab in H2 2026; data H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-274291","json":"https://secwatch.observer/filing/0001193125-26-274291.json","markdown":"https://secwatch.observer/filing/0001193125-26-274291.md","text":"https://secwatch.observer/filing/0001193125-26-274291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/0001193125-26-274291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/odtx-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:46:26.377206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0196ad87c51ce402873ef0de99b004e34d82b6f7","claim":"Odyssey Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income $38.3 million.","evidence_excerpt":"Net loss was $38.3 million for the quarter ended March 31, 2026, compared to a net loss of $38.4 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/0001193125-26-274291-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Net income","value":"$38.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}